RaQualia Pharma, The Current Fiscal Year Ordinary Profit Revised Downward to a Loss

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Dec 13, 2024 4:00 pm JST Revision

4579 RaQualia Pharma Inc. 【J-GAAP】

Guidance Update Report

RaQualia Pharma Inc. <4579> [TSE Growth] announced a performance revision after the market closed on December 13th (16:00). The consolidated ordinary profit/loss for the fiscal year ending December 2024 has been revised downward from an expected profit of 290 million yen to a loss of 476 million yen (compared to a loss of 293 million yen in the previous period), turning to a loss outlook.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the July to December period (second half) consolidated ordinary profit/loss has been revised downward from an expected profit of 567 million yen to a loss of 199 million yen (compared to a loss of 329 million yen in the same period of the previous year), turning to a loss outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2024 Prev	3,124	467	567	559	25.6	0	Aug 14, 2024	J-GAAP
Jul - Dec, 2024 New	1,724	-80	-199	-261	-12.0	0	Dec 13, 2024	J-GAAP
Revision Rate	-44.8%	－	－	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2024 Prev	4,535	313	290	236	10.8	0	Feb 14, 2024	J-GAAP
Dec, 2024 New	3,135	-234	-476	-584	-26.7	0	Dec 13, 2024	J-GAAP
Revision Rate	-30.9%	－	－	－	－

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2023	887	-314	-329	-348	-16.1	0	Feb 14, 2024	J-GAAP
Jul - Dec, 2024 Guidance	1,724	-80	-199	-261	-12.0	0	Dec 13, 2024	J-GAAP
YoY	+94.4%	+74.5%	+39.5%	+25.0%	+26.0%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	2,918	866	904	723	34.5	0	Feb 14, 2023	J-GAAP
Dec, 2023	1,901	-337	-293	-323	-15.0	0	Feb 14, 2024	J-GAAP
Dec, 2024 Guidance	3,135	-234	-476	-584	-26.7	0	Dec 13, 2024	J-GAAP
YoY	+64.9%	+30.6%	-62.5%	-80.8%	-78.5%